CompletedPhase 3NCT00006453
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
Studying Malignant non-epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AGO Study Group
- Principal Investigator
- Jacobus Pfisterer, MDUniversity Hospital Schleswig-Holstein
- Intervention
- carboplatin(drug)
- Eligibility
- 18-120 years · FEMALE
- Timeline
- 1999 – 2006
Study locations (30)
- St. Mary's/Duluth Clinic Health System, Duluth, Minnesota, United States
- Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada
- Cross Cancer Institute, Edmonton, Alberta, Canada
- Lethbridge Cancer Clinic, Lethbridge, Alberta, Canada
- British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, Canada
- Nanaimo Cancer Clinic, Nanaimo, British Columbia, Canada
- Penticton Regional Hospital, Penticton, British Columbia, Canada
- British Columbia Cancer Agency - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
- Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
- British Columbia Cancer Agency, Vancouver, British Columbia, Canada
- St. Paul's Hospital - Vancouver, Vancouver, British Columbia, Canada
- British Columbia Cancer Agency - Vancouver Island Cancer Centre, Victoria, British Columbia, Canada
- G. Steinhoff Clinical Research, Victoria, British Columbia, Canada
- CancerCare Manitoba, Winnipeg, Manitoba, Canada
- Moncton Hospital, Moncton, New Brunswick, Canada
- +15 more locations on ClinicalTrials.gov
Collaborators
European Organisation for Research and Treatment of Cancer - EORTC · NCIC Clinical Trials Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00006453 on ClinicalTrials.govOther trials for Malignant non-epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07189871177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsRadiopharm Theranostics, Ltd
- RECRUITINGPHASE1NCT07216105FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsFate Therapeutics
- RECRUITINGPHASE1NCT06238479A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsEli Lilly and Company
- ACTIVE NOT RECRUITINGPHASE2NCT06169124Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT05872204Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian CancerUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT04644289WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCAGO Research GmbH
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04180371Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionBicycleTx Limited
See all trials for Malignant non-epithelial tumor of ovary →